viernes, 13 de noviembre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 28, 2026

United States AI in Healthcare Market Forecast Report and Company Analysis 2025-2033 Featuring AWS, General Vision, Google, Intel, Medtronic, Micron, Microsoft, Next IT, NVIDIA, Siemens Healthcare

View original at finance.yahoo.com
United States AI in Healthcare Market Forecast Report and Company Analysis 2025-2033 Featuring AWS, General Vision, Google, Intel, Medtronic, Micron, Microsoft, Next IT, NVIDIA, Siemens Healthcare Company Logo The United States AI in Healthcare Market is projected to soar from US$ 10.26 billion in 2025 to US$ 99.77 bil…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The high cost of implementing AI technologies and the shortage of skilled professionals pose significant barriers to market growth.

    80% confidence

  • The United States AI in Healthcare Market is expected to reach US$ 99.77 billion by 2033 from US$ 10.26 billion in 2025, with a CAGR of 32.88% from 2025 to 2033.

    80% confidence

  • The United States is becoming a global leader in healthcare innovation as a result of the acceleration of AI integration brought about by rising healthcare costs and the expansion of big data availability.

    80% confidence

  • AI-powered precision medicine platforms are being deployed across oncology, neurology, and cardiology to identify molecular markers and optimize care delivery.

    80% confidence

  • California, Texas, New York, and Florida lead in AI healthcare adoption, bolstering U.S. AI healthcare innovation.

    80% confidence

  • One of the major challenges in the U.S. AI in Healthcare market is ensuring data privacy and compliance with complex regulations such as HIPAA and emerging state-specific laws.

    80% confidence

  • The FDA's support for AI-based medical devices and government programs encouraging healthcare digitization further accelerate industry growth.

    80% confidence

  • Rapid digital transformation, growing demand for precision medicine, robust government support, and the need for affordable healthcare solutions are the main factors propelling the U.S. AI in healthcare market.

    80% confidence

  • Many small and mid-sized hospitals struggle to afford AI technologies, leading to uneven adoption across regions.

    80% confidence

  • NLP advancements are accelerating AI adoption across the U.S. healthcare sector by transforming how unstructured clinical data is utilized.

    80% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,995
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,995 hechos verificados con la fuente5,577 documentos fuente archivados
Consulta estos datos → isubstrate.com
United States AI in Healthcare Market Forecast Report and Company Analysis 2025-2033 Featuring AWS, General Vision, Google, Intel, Medtronic, Micron, Microsoft, Next IT, NVIDIA, Siemens Healthcare — Source | Via News | es.VIA.NEWS